Brief Review of SERM Therapy Data in HR+ Metastatic Breast Cancer

EP: 1.HR+ Metastatic Breast Cancer: Overview of the Current Treatment Landscape

EP: 2.What is the Role of Oral SERD Therapy in HR+ Metastatic Breast Cancer?

Now Viewing

EP: 3.Brief Review of SERM Therapy Data in HR+ Metastatic Breast Cancer

EP: 4.Interpreting Data With CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

EP: 5.HR+ Metastatic Breast Cancer: Continuing CDK4/6 Inhibition Beyond Progression

EP: 6.Treatment for HR+ Metastatic Breast Cancer After Progression on CDK4/6 Inhibitors

EP: 7.HER2-Low Metastatic Breast Cancer and Use of Trastuzumab Deruxtecan

EP: 8.HR+ Metastatic Breast Cancer: What is the Role of Antibody-Drug Conjugates?

EP: 9.Ongoing Clinical Trials With ADC Therapy in HR+ Metastatic Breast Cancer

Transcript:

Eva M. Ciruelos Gil, MD, PhD: Lasofoxifene is not a SERD [selective estrogen receptor degraders], it’s a SERM [selective estrogen receptor modulator]. Based on any differences you’ve seen in the different drug pools, or your conclusions for SERDs and lasofoxifene data, do you see any different roles for this drug?

Sara M. Tolaney, MD, MPH: I think it’s being developed in a similar way. It seems as though the data that we saw yesterday were comparing lasofoxifene [Fablyn] with fulvestrant [Faslodex] in the ESR1-mutant population and showing pretty similar data. This may be a trend toward a benefit. But again, I think it’s an active agent that is well tolerated. I thought the data we saw at ASCO [American Society of Clinical Oncology Annual Meeting 2022] were quite impressive. This was the agent in combination with abemaciclib [Verzenio]. It is moving forward into registrational studies. As you point out, it is different. It’s a SERM, as opposed to a SERD, so I think it has a lot of potential because the abemaciclib combination data looked outstanding. We’ll have to see what happens.

Eva M. Ciruelos Gil, MD, PhD: Let’s see. Thank you very much, Sara.

Transcript edited for clarity.